# EDGAR Filing Document

**Accession Number:** 0001611746
**File Stem:** 0000000000-25-007096
**Filing Date:** 2025-7
**Character Count:** 3558
**Document Hash:** 47a2600c25976f4c690ef9330e97e18c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007096.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0000000000-25-007096

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250707

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SciSparc Ltd.
- **CENTRAL INDEX KEY:** 0001611746
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-282351

**BUSINESS ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916
- **BUSINESS PHONE:** 972-3-6103100

**MAIL ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SciSparc Ltd./ADR
- **DATE OF NAME CHANGE:** 20210129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Therapix Biosciences Ltd.
- **DATE OF NAME CHANGE:** 20140624
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-24-082318

## Text-Extract

```

                                                              July 7, 2025

Oz Adler
Chief Executive Officer
SciSparc Ltd.
20 Raul Wallenberg Street, Tower A
Tel Aviv 6971916 Israel

       Re: SciSparc Ltd.
           Amendment No. 8 to Registration Statement on Form F-4
           Filed June 25, 2025
           File No. 333-282351
Dear Oz Adler:

     We have reviewed your amended registration statement and have the
following
comment(s).

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our May 23, 2025
letter.

Amendment No. 8 to Registration Statement on Form F-4 filed June 25, 2025
Consolidated Financial Statements, page F-1

1.     Your disclosure in the filing indicates that you expect to effect a
one-for-twenty one
       reverse share split prior to the completion of the merger. Please
provide clarification
       as to when your anticipated reverse share split will be effected in
relation to the
       effectiveness of this registration statement. Please also tell us how
you anticipate
       reflecting the reverse share split retrospectively in your historical
financial statements.
       Refer to the guidance in paragraphs 26 through 29 and 64 of IAS 33 and
SAB Topic
       4. C.
       Please contact Valeria Franks at 202-551-7705 or Suying Li at
202-551-3335 if you
have questions regarding comments on the financial statements and related
matters. Please
 July 7, 2025
Page 2

contact Cara Wirth at 202-551-7127 or Donald Field at 202-551-3680 with any
other
questions.

                                                         Sincerely,

                                                         Division of
Corporation Finance
                                                         Office of Trade &
Services
cc:   Howard Berkenblit, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._